(Q50936529)

25 March 2018

title

Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. (English)

1 reference

25 March 2018

author name string

I Kobrin

1

1 reference

25 March 2018

V Charlon

2

1 reference

25 March 2018

E Lindberg

3

1 reference

25 March 2018

R Pordy

4

1 reference

25 March 2018

language of work or name

English

0 references

publication date

1 August 1997

1 reference

25 March 2018

American Journal of Cardiology

published in

1 reference

25 March 2018

volume

80

1 reference

25 March 2018

issue

4B

1 reference

25 March 2018

page(s)

40C-46C

1 reference

25 March 2018

Selective inhibition of T-type Ca2+ channels by Ro 40-5967

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Do calcium channel blockers increase the risk of cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

The risk of myocardial infarction associated with antihypertensive drug therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

The calcium channel blocker scare. Lessons for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Nifedipine and mortality. Grave defects in the dossier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Are calcium antagonists harmful in hypertensive patients? Distinguishing hype from reality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900569-9

10.1016/S0002-9149(97)00569-9

7 January 2021

Identifiers

DOI

1 reference

25 March 2018

PubMed ID

9286853

1 reference

25 March 2018